Extraembryonic Tissue cells and method of use thereof

• US 20100172830A1
• Filed: 02/08/2008
• Published: 07/08/2010
• Est. Priority Date: 03/29/2007
• Status: Abandoned Application

• Current Assignee: Anthrogenesis Corporation (Bristol-Myers Squibb Company)
• Original Assignee: Cellx, Inc.
• Inventors: Heidaran, Mohammad A.
• Application Number:
  US12/028,756
• Publication Number:
  US 20100172830A1
• Time in Patent Office: Days
• US Class Current: 424/1.170
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: A61K 49/1896 not provided for elsewhere, e.g. cells, viruses, ghosts, red blood cells, virus capsides
• CPC Class Codes: A61K 51/1203 in a form not provided for by groups A61K51/1206 - A61K51/1296, e.g. cells, cell fragments, viruses, virus capsides, ghosts, red blood cells, viral vectors
• CPC Class Codes: C12N 2533/74 Alginate
• CPC Class Codes: C12N 5/0605 Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly

Abstract

The present invention provides Pre-term Placenta Extra-embryonic Tissue Cell (PPETC) populations, and methods of culturing, proliferating and expanding the same. The invention also provides methods of using such cells for therapeutic and diagnostic applications. The present invention provides a method for isolation of extra-embryonic cell population will which are to be obtained preferably from premature discarded placenta by a process of non-enzymatic digestion or mechanical disruption. The isolated cells are cultured in semi-solid glycosaminoglycan-based three-dimensional milieu supplemented with autologous umbilical cord-derived serum. The isolated cells which are expanded in semi-solid media will be formulated for intravenous injections to patients having end stage cystic fibrosis. A preferred method of formulating cells for intravenous injection and optimal cell number are described herein. The PPETC may also used to diagnose diseased organs and elicit a robust immune response to stem cell markers commonly found in certain type of cancer stem cells.

Claims

1. An isolated and propagated cell population that is CFTR+ from pre-term discarded placenta

2. The isolated stem cell of claim 1, wherein said stem cell is LRP5/6+ and CFTR+

3. The isolated stem cell of claim 1, wherein said propagated in three-dimensional beads and supplemented with media optimized for extra-embryonic cell proliferation

4. The isolated stem cell of claim 1, wherein said cell facilitates formation of one or more extra-embryoid-like bodies when cultured in alginate beads and supplemented with serum obtained from matched umbilical cord blood.

5. Method of isolating cell of claim 1, wherein said cultured in alginate beads or similar materials and supplemented with 2-10% serum obtained from matched umbilical cord blood.

6. Method of isolating cell of claim 1, wherein said cultured in alginate beads or similar materials and supplemented with 2-10% serum obtained from matched umbilical cord blood, bFGF (10 ng/ml);

PDGF-A (30 ng/ml);

Type VI collagen (10 ug/ml) and IGF-I (30 ng/ml).

7. Method of formulating PPETC for localized implantation whereas PPETC combined with Umbilical-cord-derived plasma rich platelet preparation for local delivery or delivered in appropriate three-dimensional culture environment such as modified extracellular matrices.

8. A method of treating lung fibrosis associated with lung disease or cystic fibrosis using systemic infusion of PPETC to patients.

9. A method of using PPETC to treat cystic fibrosis patients by infusing CFTR+ positive cells systemically

10. A method of treating cystic fibrosis patent pre-birth by infusing PPETC cells into the fetus umbilicus vein directly intra-uterinely.

11. A method of diagnosing cystic fibrosis and treating fetus prebirth intra-uterinely using PPETC derived from sibling placenta.

12. A method of diagnosis for early stages of lung disease whereby culture expanded cells are labeled infused and their distribution to the lung is assessed by SPECT/CT or MRI

13. A method of diagnosis for early stages of lung disease whereby culture expanded cells are labeled by 111In oxine or quantum dot infused and their distribution to the lung is assessed by SPECT/CT or MRI 24, 48 hours, 68 hours and 124 hours post infusion

14. A method of inducing immune response to tumor stem cells in vivo by administrating irradiated PPETC population formulated in an appropriate adjuvant.

16. A method of claim 14 whereby cancer patients are diagnosed with solid tumors such as pancreatic, breast, lung, ovary, prostate and stomach.

17. A method of claim 14 whereby cancer patients are diagnosed with lung cancer such as small cell carcinoma.

18. A method of claim 14 whereby cancer patients are diagnosed and infused intra-tumorely with allogeneic PPETC

15. A method of stimulating cancer patient immune response by systemic or direct infusion of minimally or highly mismatched PPETC.

19. A method of inducing chimerism in patients using a combination of several independently derived PPETC.

20. A method of inducing chimerism in pediatric patients using a combination of several independently derived PPETC delivered intra-uterinely by direct injection of PPETC to the umbilicus vein.

21. A method of using PPETC expressing ABCG2, CFTR and or LRP5 as drug target.

22. A method by which PPETC is used to screen for antagonists or modulators of at least one of the following genes ABCG2, CFTR or LRP5.